Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

CANDA T., Yavuz E., ÖZDEMİR N., Ilvan S., Dizbay S. S., Durak M. G., ...Daha Fazla

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.14, sa.3, ss.160-165, 2018 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/ejbh.2018.3961
  • Dergi Adı: EUROPEAN JOURNAL OF BREAST HEALTH
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.160-165
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory.